Targeting Cardiometabolic Risk Beyond Statins: A Systematic Review of Evolocumab in Statin-Intolerant Patients with Metabolic Syndrome. Journal of Carcinogenesis, [S. l.], v. 24, n. 3s, p. 441–448, 2025. DOI: 10.64149/J.Carcinog.24.3s.441-448. Disponível em: https://carcinogenesis.com/index.php/JOC/article/view/761. Acesso em: 6 dec. 2025.